- Home
- PLTR vs NVS Comparison
PLTR vs NVS Comparison
Compare PLTR & NVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLTR
- NVS
- Stock Information
- Founded
- PLTR 2003
- NVS 1895
- Country
- PLTR United States
- NVS Switzerland
- Employees
- PLTR N/A
- NVS N/A
- Industry
- PLTR Retail: Computer Software & Peripheral Equipment
- NVS Biotechnology: Pharmaceutical Preparations
- Sector
- PLTR Technology
- NVS Health Care
- Exchange
- PLTR Nasdaq
- NVS Nasdaq
- Market Cap
- PLTR 364.9B
- NVS 242.8B
- IPO Year
- PLTR 2020
- NVS 1991
- Fundamental
- Price
- PLTR $158.66
- NVS $117.08
- Analyst Decision
- PLTR Hold
- NVS Hold
- Analyst Count
- PLTR 20
- NVS 6
- Target Price
- PLTR $99.11
- NVS $123.67
- AVG Volume (30 Days)
- PLTR 58.0M
- NVS 2.0M
- Earning Date
- PLTR 08-04-2025
- NVS 07-17-2025
- Dividend Yield
- PLTR N/A
- NVS 2.21%
- EPS Growth
- PLTR 92.54
- NVS N/A
- EPS
- PLTR 0.23
- NVS 6.85
- Revenue
- PLTR $3,115,024,000.00
- NVS $55,186,000,000.00
- Revenue This Year
- PLTR $38.89
- NVS $7.22
- Revenue Next Year
- PLTR $28.59
- NVS $1.94
- P/E Ratio
- PLTR $677.81
- NVS $17.11
- Revenue Growth
- PLTR 33.45
- NVS 12.95
- 52 Week Low
- PLTR $21.23
- NVS $96.06
- 52 Week High
- PLTR $160.39
- NVS $124.83
- Technical
- Relative Strength Index (RSI)
- PLTR 64.26
- NVS 47.40
- Support Level
- PLTR $153.04
- NVS $115.77
- Resistance Level
- PLTR $160.39
- NVS $118.32
- Average True Range (ATR)
- PLTR 4.92
- NVS 1.68
- MACD
- PLTR 0.44
- NVS -0.40
- Stochastic Oscillator
- PLTR 80.11
- NVS 30.80
About PLTR Palantir Technologies Inc.
Palantir is an analytical software company that focuses on leveraging data to create efficiencies in its clients' organizations. The firm serves commercial and government clients via its Foundry and Gotham platforms, respectively. Palantir works only with entities in Western-allied nations and reserves the right not to work with anyone that is antithetical to Western values. The Denver-based company was founded in 2003 and went public in 2020.
About NVS Novartis AG
Novartis develops and manufactures innovative drugs. Key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.